/AIXC

AIXC Stock - AIxCrypto Holdings, Inc.

Q: What is the analyst price target for AIXC?

Analyst price target information is not currently available for AIXC.

Q: What is AIXC's market cap?

Market capitalization information is not currently available for AIXC.

Healthcare|Medical - Pharmaceuticals|NASDAQ

$2.74+3.01%

+$0.08 (+3.01%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $3.01

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for AIXC

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.28

52W High$8.81

52W Low$1.61

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	N/A	N/A	N/A	$5.65M	$4.31M
Gross Profit	N/A	N/A	$680,801	$1.32M	$-2,879,641
Gross Margin	N/A	N/A	N/A	23.4%	-66.9%
Operating Income	$-5,761,720	$-11,304,857	$-14,760,720	$-22,663,036	$-12,679,522
Net Income	$-6,259,191	$-13,417,212	$-18,640,543	$-17,897,137	$-20,418,942
Net Margin	N/A	N/A	N/A	-316.6%	-474.2%
EPS	$-17.55	$-132.25	$-243.00	$-305.00	$-705.37

Company Overview

AIxCrypto Holdings, Inc., a clinical-stage therapeutics company, focuses on the development of treatments for adult and pediatric cancer. The company's lead program is QN-302, an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor, which is in Phase I clinical trial for the treatment of pancreatic cancer and other solid tumors. It is also developing Pan-RAS that is in preclinical stage for the treatment of advanced solid tumors. The company was formerly known as Qualigen Therapeutics, Inc. and changed its name to AIxCrypto Holdings, Inc. in November 2025. The company was founded in 1996 and is based in Carlsbad, California.

Visit Website

Earnings History & Surprises

AIXC

Beat Rate

Last 0 quarters

Avg Surprise

+0%

EPS vs Estimate

Beats / Misses

0/0

Last 12 quarters

Latest EPS

$-4.68

Q4 2025

EPS Surprise History

Q4 25

No data

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q4 2025	Nov 14, 2025	—	$-4.68	—	—

Frequently Asked Questions about AIXC

What is AIXC's current stock price?

AIxCrypto Holdings, Inc. (AIXC) is currently trading at $2.74 per share. The stock has moved +3.01% today.

What is the analyst price target for AIXC?

No analyst price targets are currently available for this stock.

What sector is AIxCrypto Holdings, Inc. in?

AIxCrypto Holdings, Inc. operates in the Healthcare sector, specifically within the Medical - Pharmaceuticals industry. The company is traded on the NASDAQ exchange.

What is AIXC's market cap?

AIxCrypto Holdings, Inc. has a market capitalization of $0.01 billion, making it a small-cap company.

Does AIXC pay dividends?

No, AIxCrypto Holdings, Inc. does not currently pay a dividend to shareholders.